PatternsRadar
Sign in

WINDLASWindlas Biotech Limited

NSE
Full chart
1,036.20INR+18.30 (+1.80%)Close · 6 Oct 2026
10 Aug 2026Last results
HealthcareSector
Pharmaceuticals & BiotechnologyIndustry
₹2,138 CrMarket cap
32.2P/E (TTM)
46.6%Delivery

Filings & corporate actions

21 results filed
CSV
Next results · Q2 FY27
Expected 2 Nov 2026 – 12 Nov 2026
Estimate: filed 33–43 days after quarter end, last 5 times
Dividend
₹6.30 per share · last 16 Jul 2026
2026
  • 10 AugresultsResults · Q1 FY27 · standalone+12.3%NSE
  • 16 JulshareholdingShareholding · 30 Jun 2026+1.2%NSE
  • 16 JuldividendDividend · ₹6.30 per share+1.2%
  • 26 MayshareholdingShareholding · 18 May 2026+4.8%NSE
  • 21 MayresultsResults · Q4 FY26 · consolidated and standalone+1.0%NSE
  • 24 AprbuybackBuy Back-3.9%
  • 15 AprshareholdingShareholding · 31 Mar 2026+6.4%NSE
  • 5 FebresultsResults · Q3 FY26 · consolidated and standalone+2.0%NSE
  • 20 JanshareholdingShareholding · 31 Dec 2025-5.7%NSE

Reaction to results · all yearsrose on day 0 in 11 of 21 CSV

QuarterFiledDay 0+5D+20DRel vol
Q1 FY2710 Aug 2026+12.3%+9.3%+36.5%55.4×
Q4 FY2621 May 2026+1.0%+3.9%+9.6%4.6×
Q3 FY265 Feb 2026+2.0%-3.8%-12.6%2.0×
Q2 FY266 Nov 2025-5.7%-11.1%-16.6%9.2×
Q1 FY2612 Aug 2025+11.9%+7.0%+5.1%18.8×
Q4 FY2522 May 2025-5.5%-6.0%-8.9%8.4×
Q3 FY2511 Feb 2025+1.9%-19.8%+6.1%3.0×
Q2 FY2512 Nov 2024+1.8%-2.8%+5.4%1.3×
Q1 FY2513 Aug 2024-12.0%-6.5%+3.9%4.9×
Q4 FY2420 May 2024+9.9%+11.1%+26.5%17.1×
Q3 FY248 Feb 2024-2.5%-2.5%+7.0%2.1×
Q2 FY248 Nov 2023-0.8%+8.0%+8.6%1.3×
Q1 FY249 Aug 2023+5.2%+18.3%+12.8%3.0×
Q4 FY236 May 2023+3.3%+5.0%+9.3%5.1×
Q3 FY239 Feb 2023+3.4%+5.9%+4.5%3.7×
Q2 FY239 Nov 2022-0.1%-5.2%+1.7%3.5×
Q1 FY234 Aug 2022-1.8%-3.4%+7.6%1.4×
Q4 FY2212 May 2022+5.4%+5.9%+6.1%2.3×
Q3 FY223 Feb 2022-0.9%+7.7%-10.3%1.9×
Q2 FY222 Nov 2021-0.6%-1.9%-9.8%1.2×
Q1 FY228 Sept 2021-2.7%-2.9%-9.3%—
Average+1.2%+0.8%+4.0%

Close-to-close from the session before the filing could trade. Day 0 is the first session after it.

Growth · Q4 FY26

CSV
Revenue YoY+18.1%
Profit YoY-0.1%
Interest cost YoY+9.5%
Revenue QoQ+4.0%
Profit QoQ+10.2%
CAGR2Y3Y4Y5Y6Y7Y
Revenue+19.4%+20.5%————
Profit+5.6%+13.9%————

Key data

CSV
Open1,008.00
Day range1,000.00 – 1,041.00
52-week range697.40 – 1,181.90
From 52w high-12.3%
RSI (14)44.4
ATR (14)47.37
Volume71.9K
Avg volume (20D)97.3K
Rel volume0.74×
Volatility (1Y)35.9%
Turnover₹7.4Cr
SMA 50 / 2001,006.69 / 856.99

Delivery percentage

Latest · 6 Oct 202646.6%
20-day avg47.6%
1-year avg54.9%
Percentile (own history)26th
Range12.2–92.9%
Sessions1,270

Over the last 20 sessions WINDLAS settled 47.6% of its traded quantity, which is above average for an NSE equity. Its one-year average is 54.9%, so recent sessions are running 7.3 points lower than usual. The latest session ranks higher than 26% of the 1,270 sessions on record for it.

What delivery percentage measuresScan the whole market on delivery

IndustryPharmaceuticals
PeersDIVISLABLAURUSLABSSUNPHARMAWOCKPHARMADRREDDYMOREPENLAB

Performance returns

CSV
1D1W1M3M6M1Y
Price+1.80%-6.02%-8.06%+21.34%+35.54%+12.30%

Valuation

CSV
Market cap₹2,138 Cr
P/E (TTM)32.2
EPS (TTM)32.19
Shares outstanding2.11Cr
Listed16 Aug 2021

Ownership

CSV
Promoter63.31%
Promoter Δ QoQ0.00 pp
Public36.69%
FII2.04%
DII9.84%
Pledged0.00%

Quarterly results · consolidated

CSV
Q1 FY26Q2 FY26Q3 FY26Q4 FY26
Revenue (₹ Cr)210.1222.4233.1238.5
YoY chg+19.9%+18.9%+19.5%+17.7%
Net profit (₹ Cr)17.717.815.016.0
YoY chg+31.0%+13.7%-3.7%-1.8%
Net margin8.4%8.0%6.4%6.7%
EPS8.348.407.057.49

Shareholding over time

CSV

By quarter

30 Jun 2026 · promoter 63.31% · public 36.69%
30 Sept 2021: promoter 59.95%31 Dec 2021: promoter 59.95%31 Mar 2022: promoter 59.95%30 Jun 2022: promoter 59.95%30 Sept 2022: promoter 59.95%31 Dec 2022: promoter 60.75%15 Feb 2023: promoter 61.22%31 Mar 2023: promoter 62.38%10 Apr 2023: promoter 62.44%30 Jun 2023: promoter 62.82%30 Sept 2023: promoter 62.82%31 Dec 2023: promoter 62.82%31 Mar 2024: promoter 62.82%30 Jun 2024: promoter 62.51%30 Sept 2024: promoter 62.51%31 Dec 2024: promoter 62.51%31 Mar 2025: promoter 62.34%30 Jun 2025: promoter 62.34%30 Sept 2025: promoter 61.99%31 Dec 2025: promoter 61.99%31 Mar 2026: promoter 61.90%18 May 2026: promoter 63.31%30 Jun 2026: promoter 63.31%
2021-092026-06
  • Promoter
  • Public and others
Promoter
63.31%
Public
36.69%
Promoter change
0.00 pp
Filed
16 Jul 2026
FII
2.04%
DII
9.84%
Promoter pledged
0.00%

Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.

Financials · quarterly statement

CSV
₹ crore, as filed
 Q1 FY24Q2 FY24Q3 FY24Q4 FY24AQ1 FY25Q2 FY25Q3 FY25Q4 FY25AQ1 FY26Q2 FY26Q3 FY26Q4 FY26A
Revenue from operations144.8152.7162.2171.3175.2187.0195.0202.7210.1222.4233.1238.5
Other income2.63.23.24.44.14.84.14.95.23.64.64.4
Total income147.4155.9165.4175.7179.3191.8199.1207.6215.3226.0237.7242.8
Total expenses131.1137.6145.6153.1161.0171.6178.8186.8192.1202.5217.7222.7
└ Finance costs0.20.30.30.30.51.11.51.31.11.01.31.5
└ Depreciation3.23.33.43.56.26.56.98.37.47.67.78.0
Profit before tax16.318.319.822.618.320.320.320.823.323.620.020.2
Tax expense4.34.34.75.64.84.64.84.55.65.85.04.2
Net profit12.114.015.117.013.515.715.616.317.717.815.016.0
EPS5.796.757.268.176.477.497.457.778.438.487.127.58
Net margin8.33%9.19%9.31%9.92%7.70%8.37%7.99%8.03%8.41%8.00%6.44%6.70%
PBT margin11.29%11.99%12.21%13.21%10.45%10.85%10.43%10.27%11.07%10.61%8.57%8.45%
Tax rate26.16%23.38%23.77%24.92%26.39%22.81%23.41%21.81%24.05%24.54%24.88%20.69%

A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 21 May 2026.

WINDLAS at a glance

  • WINDLAS closed at ₹1,036.2 on 6 Oct 2026, +1.80% on the day, +12.3% over one year, 12.3% below its 52-week high of ₹1,181.9.
  • Delivery was 46.6% of traded quantity on 6 Oct 2026, the 26th percentile of its own 1,270 sessions with a reading (20-session average 47.6%, 1-year average 54.9%).
  • Market capitalisation is ₹2,138 crore at a trailing P/E of 32.2 (trailing EPS ₹32.19).
  • Q4 FY26 results (consolidated, filed 21 May 2026): revenue ₹238 crore (+17.7% year on year), net profit ₹16 crore (-1.8%); the price moved +1.0% on the first session after.
  • Promoters held 63.31% at 30 Jun 2026, unchanged on the previous filing.
  • Q2 FY27 results are expected between 2 Nov 2026 and 12 Nov 2026, going by past filing dates — an estimate, not an announcement.

About

CSV
Macro sectorHealthcare
Basic industryPharmaceuticals
ISININE0H5O01029
SeriesEQ
Listed16 Aug 2021
History from16 Aug 2021
Sessions1,274

Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.

More in Pharmaceuticals & Biotechnology

CSV

All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE